IMMUNOTHERAPY BRIDGE
December 1st-2nd, 2021
Presidents
Paolo A. Ascierto
Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy
Bernard A. Fox
Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US
Patrick Hwu
Patrick Hwu, MD, President & CEO, Moffitt Cancer Center, Tampa, Florida, US
Igor Puzanov
Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA
Scientific Board
Sanjiv Agarwala
Professor, Temple University, Philadelphia, Pennsylvania, US
Paolo A. Ascierto
Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy
Carlo Bifulco
Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, US -> anche nel Board sia di Melanoma che di Immuno
Elizabeth Burton
Director, Melanoma Research Planning & Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US
Lisa H. Butterfield
Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, US
Corrado Caracò
Chief of Surgery of Melanoma and Skin Cancer Unit, Dept of Haematology and Developmental Therapeutics, National Cancer Institute “Fondazione Pascale”, Naples, Italy
Sandra Demaria
Department of radiation oncology and pathology and laboratory medicine, Weill Cornell Medicine, New York, New York, US
Reinhard Dummer
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland
Bernard A. Fox
Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US
Jerome Galon
Research Director, National Institute of Health and Medical Research (INSERM), Paris, France
Claus Garbe
Professor of Dermatology, Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
Omid Hamid
Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, California, USA
Patrick Hwu
Patrick Hwu, MD, President & CEO, Moffitt Cancer Center, Tampa, Florida, US
Giuseppe Masucci
Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
Giuseppe Palmieri
President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy
Iman Osman
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York City, New York, US
Michael Postow
Memorial Sloane Kettering Cancer Center, New York City, New York, US
Igor Puzanov
Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA
Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland, USA
Tara Withington
Executive Director of Society of Immunotherapy for Cancer (SITC), Milwaukee, Wisconsin, USA
For information please contact info@melanomabridge.org
